Pathophysiological mechanisms of hepatic encephalopathy
T.H. Tranah, A. Paolino, Debbie L. Shawcross – 21 April 2015 – Watch a video presentation of this article
A new VETC in hepatocellular carcinoma metastasis
Kaisa L. Hanley, Gen‐Sheng Feng – 21 April 2015
Diagnosing covert hepatic encephalopathy
Mette Munk Lauridsen, Hendrik Vilstrup – 21 April 2015 – Watch a video presentation of this article
Laparoscopic distal pancreatectomy
Rizwan Ahmed, Christi M. Walsh, Martin A. Makary – 21 April 2015 – Watch a video presentation of this article
Impact of minimal/covert hepatic encephalopathy on patients with cirrhosis
Radha K. Dhiman – 21 April 2015 – Watch a video presentation of this article
Diagnosing covert hepatic encephalopathy
Mette Munk Lauridsen, Hendrik Vilstrup – 21 April 2015 – Watch a video presentation of this article
Prevention of hepatic encephalopathy recurrence
Barjesh Chander Sharma, Sudhir Maharshi – 21 April 2015 – Watch a video presentation of this article
Nuclear factor kappa B–mediated CD47 up‐regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice
Jessica Lo, Eunice Yuen Ting Lau, Rachel Hiu Ha Ching, Bowie Yik Ling Cheng, Mark Kin Fai Ma, Irene Oi Lin Ng, Terence Kin Wah Lee – 21 April 2015 – Sorafenib is a new standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the survival benefit of this treatment is modest, partly owing to drug resistance. Recent evidence has demonstrated the existence of tumor‐initiating cells (T‐ICs) as the culprit for treatment resistance.
Management of hepatic encephalopathy as an inpatient
Oliviero Riggio, Silvia Nardelli, Stefania Gioia, Cristina Lucidi, Manuela Merli – 21 April 2015 – Watch a video presentation of this article